TrialArquivos brasileiros de cardiologia2016

In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study.

Igor Matos Lago et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.